AffyMax Overview
- Founded
-
2001

- Status
-
Public
- Employees
-
72

- Stock Symbol
-
AFFY

AffyMax General Information
Description
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
PINX
Primary Office
- 600 Fifth Avenue
- 2nd Floor
- New York, NY 10020
- United States
+1 (650) 000-0000
AffyMax Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
24.7K |
AffyMax Financials Summary
In Thousands, USD |
TTM 30-Jun-2014 | FY 2013 31-Dec-2013 | FY 2012 31-Dec-2012 | FY 2011 31-Dec-2011 |
---|---|---|---|---|
EV | (1,051) | 22,390 | 636,650 | 120,931 |
Revenue | 42 | 1,369 | 94,370 | 47,720 |
EBITDA | 2,694 | (14,316) | (90,086) | (59,209) |
Net Income | 2,694 | (14,424) | (93,412) | (61,367) |
Total Assets | 5,384 | 7,443 | 118,217 | 118,995 |
Total Debt | 0 | 0 | 8,844 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
AffyMax Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
AffyMax Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for
Pharmaceuticals
New York, NY
72
As of 2015
00000
000000000
00000
AffyMax Competitors (13)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Akelos (Drug Discovery) | Angel-Backed | New York, NY | 0 | 00000 | 0000000000 | 00000 |
0000 | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 00000000000 | 00000 |
0000000 0000000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 000.00 | 00000000000 | 000.00 |
0000 000000000000 | Formerly VC-backed | Waltham, MA | 00 | 00000 | 00000000 | 00000 |
0000000 | Formerly VC-backed | Leuven, Belgium | 00 | 00000 | 000000&0 | 00000 |
AffyMax Patents
AffyMax Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20090209457-A1 | Treatment of anti-erythropoietin antibody-mediated disorders with synthetic peptide-based epo receptor agonists | Abandoned | 15-Feb-2008 | 000000000 | |
JP-2009191056-A | Therapy of disorder mediated by anti-erythropoietin antibody using epo receptor agonist based on synthetic peptide | Pending | 15-Feb-2008 | 000000000 | |
US-20090124709-A1 | Analytical methods for validating excipient purity | Abandoned | 10-Sep-2007 | 000000000 | |
US-20090042802-A1 | Compounds and peptides that bind the kgf receptor | Abandoned | 22-Jun-2007 | 000000000 | |
US-20090131317-A1 | Compounds and peptides that bind the trail receptor | Abandoned | 22-Jun-2007 | C07K14/70575 | 00 |
AffyMax Executive Team (28)
AffyMax Board Members (17)
Name | Representing | Role | Since |
---|---|---|---|
Christine van Heek | Self | Board Member | 000 0000 |
Hollings Renton | Self | Chairman & Board Member | 000 0000 |
John Orwin | Self | Board Member | 000 0000 |
John Walker | Self | Board Member | 000 0000 |
Richard Brenner | AffyMax | Chief Executive Officer & Board Member | 000 0000 |
AffyMax Signals
AffyMax Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|